Combination of potassium oxonate with anti-PD-1 for the treatment of colorectal cancer

Combination of potassium oxonate with anti-PD-1 for the treatment of colorectal cancer

IntroductionIdentification of effective therapies for colorectal cancer (CRC) remains an urgent medical need, especially for the microsatellite stable (MSS) phenotype. In our previous study, potassium oxonate (PO), a uricase inhibitor commonly used for elevating uric acid in mice, unexpectedly showe...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yuanyuan Wang, Chenxi Hu, Tianpeng Du, Jiawen Li, Kaiyuan Hui, Xiaodong Jiang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-02-01
Series:	Frontiers in Oncology
Subjects:	anti-PD-1 CRC immunotherapy immune microenvironment potassium oxonate
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1528004/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Patient-derived colorectal microtumors predict response to anti-PD-1 therapy
by: Duy T. Nguyen, et al.
Published: (2025-08-01)

ANTIHYPERURICEMIC EFFECT OF RED GINGER POWDER AND LIME JUICE COMBINATION IN WISTAR RATS INDUCED HYPERURICEMIA
by: Eva Susanty Purba, et al.
Published: (2021-01-01)

Perspectives of Targeting Autophagy as an Adjuvant to Anti-PD-1/PD-L1 Therapy for Colorectal Cancer Treatment
by: Nasrah ALKhemeiri, et al.
Published: (2025-05-01)

Establishment and optimization of a novel mouse model of hyperuricemic nephropathy
by: Jiamin Wang, et al.
Published: (2024-12-01)

Targeting Hyperuricemia and NLRP3 Inflammasome in Gouty Arthritis: A Preclinical Evaluation of Allopurinol and Disulfiram Combination Therapy
by: Yahya I. Asiri, et al.
Published: (2025-05-01)

Exploring the efficiency of Oxone®/KI as a promoter in the synthesis of spirocyclopropylbarbiturate derivatives via Michael-initiated reaction cyclization (MIRC)
by: Amin Rezaeifard, et al.
Published: (2025-07-01)

Comparison of treatment outcome between first‐line combination immunotherapy (anti‐PD‐L1 or anti‐PD1) with or without chemotherapy and chemotherapy alone in advanced non‐small cell lung cancer patients in tertiary care hospital
by: Danainut Naratornsirakul, et al.
Published: (2024-07-01)

Pseudomonas aeruginosa enhances anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8+ T cells
by: Lu Chen, et al.
Published: (2025-03-01)

Tertiary lymphoid structures in the microenvironment of colorectal cancer: exploring new therapeutic targets
by: Nan-Nan Dai, et al.
Published: (2025-06-01)

Relative expression orderings based prediction of treatment response to Anti-PD-1 immunotherapy in advanced melanoma
by: Yaru Gao, et al.
Published: (2025-03-01)

Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies
by: Yizhou Zhang, et al.
Published: (2024-12-01)

Upregulation of RIG‐I is Critical for Responsiveness to IFN‐α Plus Anti‐PD‐1 in Colorectal Cancer
by: Haihang Nie, et al.
Published: (2025-03-01)

Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status
by: David Dora, et al.
Published: (2023-12-01)

NIVO-TIL: combination anti-PD-1 therapy and adoptive T-cell transfer in untreated metastatic melanoma: an exploratory open-label phase I trial
by: Jean-Matthieu L'Orphelin, et al.
Published: (2024-11-01)

Lacticaseibacillus paracasei sh2020 induced antitumor immunity and synergized with anti-programmed cell death 1 to reduce tumor burden in mice
by: Shi-Long Zhang, et al.
Published: (2022-12-01)

Reversing VTN deficiency inhibits the progression of pancreatic cancer and enhances sensitivity to anti-PD1 immunotherapy
by: Siqi Zhao, et al.
Published: (2025-05-01)

Next Generation of Colorectal Cancer Management: Integrating Omics, Targeted Therapies, and Smart Technologies
by: Tamer A. Addissouky
Published: (2024-12-01)

Inhibition of CCT5-mediated asparagine biosynthesis and anti-PD-L1 produce synergistic antitumor effects in colorectal cancer
by: Yujie Zhang, et al.
Published: (2025-05-01)

Cholesterol: The driving force behind the remodeling of tumor microenvironment in colorectal cancer
by: Ke Wang, et al.
Published: (2024-12-01)

Spotlight on nuclear PD-L1 in ovarian cancer chemoresistance: hidden but mighty
by: Meshach Asare-Werehene, et al.
Published: (2025-07-01)

The colorectal cancer microenvironment: Preclinical progress in identifying targets for cancer therapy
by: Abdo Meyiah, et al.
Published: (2025-03-01)

Fusobacterium nucleatum Enrichment in Colorectal Tumor Tissue: Associations With Tumor Characteristics and Survival Outcomes
by: Amanda I. Phipps, et al.
Published: (2025-01-01)

Sex-Related Differences in the Immune System Drive Differential Responses to Anti-PD-1 Immunotherapy
by: Sonja Cotra, et al.
Published: (2024-11-01)

Novel Pt@PCN-Cu-induced cuproptosis amplifies αPD-L1 immunotherapy in pancreatic ductal adenocarcinoma through mitochondrial HK2-mediated PD-L1 upregulation
by: Pengyu Wang, et al.
Published: (2025-05-01)

The Potential of PD-1 and PD-L1 as Prognostic and Predictive Biomarkers in Colorectal Adenocarcinoma Based on TILs Grading
by: Nur Rahmah Rasyid, et al.
Published: (2024-11-01)

Targeting the atypical chemokine receptor 2 (Ackr2) improves the benefit of anti-PD-1 immunotherapy in melanoma mouse model
by: Muhammad Zaeem Noman, et al.
Published: (2025-12-01)

Enhancing CAR-T Efficacy: The Role of Anti PD-1/PD-L1 Checkpoint Inhibitors in Modern Cancer Treatment
by: Rishi Kant, et al.
Published: (2025-06-01)

The current status and prospects of gut microbiota combined with PD-1/PD-L1 inhibitors in the treatment of colorectal cancer: a review
by: Min Deng, et al.
Published: (2025-05-01)

Efficacy and safety of PD-1 and PD-L1 inhibitors in advanced colorectal cancer: a meta-analysis of randomized controlled trials
by: Zhenzi Wang, et al.
Published: (2024-12-01)

Efficacy and safety of cadonilimab (PD-1/CTLA-4 bi-specific antibody) and adjuvant anti-angiogenesis therapy in treated, recurrent, or metastatic cervical cancer
by: Fang Zhou, et al.
Published: (2025-06-01)

ADAP and SKAP55 deficiency suppresses PD‐1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti‐tumor immunotherapy
by: Chunyang Li, et al.
Published: (2015-04-01)

Cathepsin S regulates antitumor immunity through autophagic degradation of PD-L1 in colorectal cancer cells
by: Sina Taheri Baghmisheh, et al.
Published: (2025-08-01)

ROLE OF PD-L1 ASSESSMENT IN THE ASPECT OF MOLECULAR-GENETIC CLASSIFICATION OF COLORECTAL CANCER. CURRENT STATE OF THE PROBLEM
by: S. V. Vtorushin, et al.
Published: (2021-03-01)

Visualization of PD-L1-positive and PD-1-positive immune cell contact in the breast cancer microenvironment
by: A. Yu. Kalinchuk, et al.
Published: (2024-03-01)

RBM47 functions as an anti-oncogene by regulating expression and alternative splicing of cell proliferation and apoptosis associated genes in colorectal cancer cells
by: Guangshi Liu, et al.
Published: (2025-07-01)

Lipid metabolic reprogramming in colorectal cancer: mechanisms and therapeutic strategies
by: Wujianhong Liu, et al.
Published: (2025-07-01)

Platelet‐to‐Neutrophil Ratio: A Novel Prognostic Indicator for Anti‐PD‐1‐Based Therapy in Relapsed/Refractory Hodgkin Lymphoma and Solid Tumors
by: Yuting Pan, et al.
Published: (2025-06-01)

Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma
by: Jacek Mackiewicz, et al.
Published: (2017-03-01)

Effects of Biochar Amendment on Potassium Supply Capacity and Potassium Accumulation in Soybean Across Diverse Soils
by: Liqun Xiu, et al.
Published: (2025-06-01)

High-dose Vitamin C inhibits PD-L1 expression by activating AMPK in colorectal cancer
by: Jia Huang, et al.
Published: (2025-05-01)